Related Experiment Videos
Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo
C Bass1, G Cabrera, A Elgavish
1Comprehensive Cancer Center, University of Alabama, Birmingham 35294, USA.
Abstract:
Transitional cell carcinoma (TCC) of the bladder is associated with characterized lesions in dominant and recessive oncogenes. The understanding of the molecular basis of tumorigenesis in these instances makes possible the application of gene therapy strategies for TCC. In this regard, the ability to directly access the epithelium of the genitourinary (GU) tract via the urethra provides a practical means to implement these various gene therapy approaches. We thus explored vector strategies to accomplish direct in vivo transduction of GU epithelium. Initially, three human (HT 1197, HT 1376, T24) and one mouse (MBT-2) TCC cell lines were transduced using a recombinant adenoviral vector expressing the firefly luciferase reporter gene, rAd-CMV-Luc. In these studies, reporter gene expression was found to be significantly elevated above background for all four cell lines. Of note, the TCC cell lines HT 1197 and HT 1376 showed expression levels comparable with the cervical carcinoma cell line HeLa, a cell line previously shown to be highly susceptible to recombinant adenovirus-mediated gene transduction. An in vitro time course for T24 and MBT-2 using rAd-CMV-Luc showed peak expression 1 day after transduction for the T24 line and 3 days after transduction for the MBT-2 line, with detectable levels of expression persisting for at least 7 days. As a next step, human and mouse primary tissue deriving from the GU epithelium were transduced using rAd-CMV-Luc. In this assay, luciferase expression levels significantly above background were observed in both instances.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
This study demonstrates that recombinant adenoviral vectors can effectively transduce genitourinary (GU) epithelium, showing promise for gene therapy in transitional cell carcinoma (TCC) of the bladder.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Transitional cell carcinoma (TCC) of the bladder involves oncogene mutations.
- Understanding tumorigenesis enables gene therapy strategies for TCC.
- The genitourinary (GU) tract epithelium is accessible via the urethra for gene therapy.
Purpose of the Study:
- To explore vector strategies for direct in vivo transduction of GU epithelium.
- To assess the efficacy of recombinant adenoviral vectors for gene delivery to TCC and GU tissues.
Main Methods:
- Transduction of four TCC cell lines (HT 1197, HT 1376, T24, MBT-2) and primary GU epithelium using a recombinant adenoviral vector (rAd-CMV-Luc) expressing luciferase.
- In vitro time course analysis of reporter gene expression.
Main Results:
- All four TCC cell lines exhibited significantly elevated luciferase expression.
- HT 1197 and HT 1376 cell lines showed expression levels comparable to HeLa cells.
- Detectable luciferase expression persisted for at least 7 days in T24 and MBT-2 cell lines.
- Primary human and mouse GU epithelium showed significant luciferase expression.
Conclusions:
- Recombinant adenoviral vectors are effective for transducing TCC cell lines and GU epithelium.
- This vector strategy holds potential for in vivo gene therapy applications in the GU tract.